Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome, Behcet's Disease, Bowel-associated Dermatosis-arthritis Syndrome, Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, Keratoderma Blenorrhagicum, Sneddon-Wilkinson Disease, IgA Pemphigus, Amicrobial Pustulosis of the Folds, Infantile Acropustulosis, Transient Neonatal Pustulosis, Neutrophilic Eccrine Hidradenitis, Rheumatoid Neutrophilic Dermatitis, Neutrophilic Urticaria, Still's Disease, Erythema Marginatum, Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes, Dermatitis Herpetiformis, Linear IgA Bullous Dermatosis, Bullous Systemic Lupus Erythematosus, Inflammatory Epidermolysis Bullosa Aquisita, Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis), Small Vessel Vasculitis Including Urticarial Vasculitis, Erythema Elevatum Diutinum, Medium Vessel Vasculitis
Conditions
Brief summary
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a discovery cohort formed based on the certainty of diagnosis. The DNA of patients in the discovery cohort is analyzed by whole exome sequencing which identifies all protein-coding genetic variants. Subsequently, statistical burden tests are going to identify enrichment of rare coding genetic variants in patients affected by Neutrophil-Mediated Inflammatory Skin Diseases. The ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical intervention.
Detailed description
Timeframe: * Collection of DNA for discovery cohort until 05/2016 * Data analysis until 12/2014 for pyoderma gangrenosum, until 12/2016 for other NMID * Report and data presentation early 2015 for PG, 2017 for other NMID
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* History of NMID or active disease. * Informed consent.
Exclusion criteria
\- No consent to either part of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Enrichment of rare coding genetic variants | baseline | Whole exome sequencing is going to detect rare coding genetic variants in cases of Neutrophil-Mediated Inflammatory Skin Diseases. Statistical burden tests are applied to test for excess of rare variants in cases versus available controls of matching ancestry. |
Countries
Switzerland